Zhang Lei, Han Yong, Zhao Zhijun, Liu Xiangqun, Xu Yahui, Cui Guimei, Zhang Xiangyang, Zhang Ruiling
Department of Clinical Nutrition, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Department of Psychiatry, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Asia Pac J Clin Nutr. 2020;29(3):505-512. doi: 10.6133/apjcn.202009_29(3).0009.
Konjac powder has the effect of improving blood lipids in the general population, but there is no research on schizophrenic patients who are susceptible to dyslipidemia. The aim of our study is to evaluate the effects of konjac powder on blood lipid, glucose levels, body weight, and blood pressure in schizophrenia inpatients with dyslipidemia.
After a two-week adaptation period, 76 people with schizophrenia were enrolled in a 30-day double-blind randomized controlled trial. The subjects in the experimental group were given a beverage containing konjac powder 30 minutes before each meal, whereas those in the control group were given a beverage containing resistant maltodextrin.
The lipid profile, plasma glucose, blood pressure, and body weight were measured at baseline and at the end of 30-day treatment. Fiftynine subjects completed the study. There was a substantial decrease in total serum cholesterol in the experimental group, but an increase in the control group. Likewise, apolipoprotein B decreased in the experimental group but increased in the control group.
We concluded that a diet supplemented with konjac powder may prevent the deterioration of dyslipidemia in people with schizophrenia, demonstrating its potential value in the treatment of metabolic disorders in schizophrenia as a new therapeutic method.
魔芋粉对普通人群有改善血脂的作用，但对于易患血脂异常的精神分裂症患者尚无相关研究。我们研究的目的是评估魔芋粉对血脂异常的精神分裂症住院患者的血脂、血糖水平、体重和血压的影响。
经过两周的适应期后，76名精神分裂症患者参加了一项为期30天的双盲随机对照试验。实验组的受试者在每餐饭前30分钟饮用含有魔芋粉的饮料，而对照组的受试者则饮用含有抗性麦芽糊精的饮料。
在基线和30天治疗结束时测量血脂、血糖、血压和体重。59名受试者完成了研究。实验组的总血清胆固醇大幅下降，而对照组则上升。同样，实验组的载脂蛋白B下降，而对照组上升。
我们得出结论，补充魔芋粉的饮食可能预防精神分裂症患者血脂异常的恶化，证明其作为一种新的治疗方法在精神分裂症代谢紊乱治疗中的潜在价值。
